Navigation Links
Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
Date:5/7/2013

SEATTLE, May 7, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the formation of Phyto Pharmacare, Inc., a Delaware corporation, which will oversee all aspects of developing and marketing Phytofare™ extracts for pharmaceutical and drug applications.

Plandai Chief Executive Officer Roger Duffield commented, "As a management team, we felt it necessary to differentiate the purely pharmaceutical operations from our farming, production and nutraceutical business. Taking our Phytofare™ extracts and seeking FDA clearance to market them to treat specific diseases brings unique challenges and requires an entirely different focus. The creation of Phyto Pharmacare, which will operate under a license from Plandai, enables that division to focus on specific drug targets and take our products through the various stages of clinical trials and FDA approval."

Initially, Phyto Pharmacare will focus on using its Phytofare™ Catechin Extract as both a cure for and prevention of malaria.  Malaria is a parasite infection transmitted by mosquitoes and primarily located in sub-Sahara Africa and southern Asia, where it results in nearly a million deaths annually. 

Mr. Duffield explained, "Malaria is one of great plagues that still kills way too many people, most of whom are children and the elderly located in some of the poorest and most remote areas of the world where access to life-saving medicine is either unaffordable or unavailable.  With drug-resistant strains of the parasite now spreading across Asia, we could soon be facing a pandemic.  The catechins found in green tea are well documented for their anti-malarial properties, but low human bioavailability (absorption) has limited its effectiveness as a drug.  We believe that the high bioavailability of our Phytofare™ extract will finally yield a suitable drug for treating not only malaria but also other blood-borne parasitic infections."

Phyto Pharmacare will shortly begin validating the bioavailability of Phytofare™ Catechin Extract in human studies and is just completing in-vitro studies of its anti-malarial properties compared against other catechin extracts at St. George's University of London in England. 

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.  For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact: 
Andrew Beyer
Phone: 619-202-7456
Email:  investor@Plandaibiotech.com


'/>"/>
SOURCE Plandai Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
2. Rigel Announces First Quarter 2013 Financial Results
3. Mindray Announces First Quarter 2013 Financial Results
4. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
5. Hologic Announces Second Quarter Fiscal 2013 Operating Results
6. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
7. AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
8. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
9. Apollo Medical Holdings Announces Record Fiscal Year-End Results
10. Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
11. Premier Home Medical Supply Vendor Med Supply Shop Announces Drive Spring Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would ... results in a fraction of the time as traditional braces – Wilckodontics®. Dr. ... Specialists, now offers this revolutionary treatment with or without a referral. , ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place ... to a special report in the May issue of Consumer Reports focused on heart ... ranking for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
Breaking Medicine News(10 mins):